Y Intercept (Hong Kong) LTD Alnylam Pharmaceuticals, Inc. Transaction History

Y Intercept (Hong Kong) LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $6.24 Million - $10.8 Million	43,545 Added 1531.66%	46,388 $11.3 Million
Q1 2024 May 10, 2024	BUY	$146.51 - $198.2 $144,751 - $195,821	988 Added 53.26%	2,843 $424,000
Q4 2023 Feb 13, 2024	BUY	$151.41 - $196.57 $280,865 - $364,637	1,855 New	1,855 $355,000
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $1.1 Million - $1.43 Million	-5,935 Closed	0 $0
Q3 2022 Feb 14, 2023	BUY	$138.54 - $232.0 $822,234 - $1.38 Million	5,935 New	5,935 $1.19 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $398,582 - $545,033	-3,134 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $500,061 - $655,914	3,134 New	3,134 $531,000
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $1.29 Million - $1.58 Million	-7,592 Closed	0 $0
Q2 2021 Aug 26, 2021	BUY	$128.63 - $176.89 $976,558 - $1.34 Million	7,592 New	7,592 $1.29 Million
Q2 2021 Aug 12, 2021	SELL	$128.63 - $176.89 $483,648 - $665,106	-3,760 Closed	0 $1.29 Million
Q1 2021 May 12, 2021	BUY	$126.83 - $175.69 $476,880 - $660,594	3,760 New	3,760 $508,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.